Clinical trials
Endometrial Clear Cell Adenocarcinoma clinical trials
Below are recruiting endometrial clear cell adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 20 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06730347RecruitingPhase 2
Study of lorigerlimab for advanced ovarian and other cancers
This trial tests a new drug, lorigerlimab, for people with certain types of ovarian cancer or related cancers that have come back or not responded to treatment. The goal is to see if the drug can help shrink tumors or slow the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT05950464RecruitingPhase 1
Dose study of two targeted drugs for recurrent ovarian cancer
This Phase 1 trial tests different doses of two study drugs (M1774 and ZEN-3694) for recurrent ovarian cancer and some recurrent endometrial cancers. It aims to find a safe dose and see how well the treatment works, especially in cancers with certain tumor features.
Augusta, GeorgiaAges 18 years+ - NCT05856981RecruitingPhase 1
Testing ADU-1805 for advanced solid tumors safety
This early study tests whether ADU-1805 is safe in people with advanced solid tumors and checks how the body processes the drug. Depending on your cancer type, it may also be looking specifically at certain cancers that have not yet received PD-(L)1 immunotherapy.
Detroit, MichiganAges 18 years+ - NCT03422198RecruitingPhase 3
Short course vaginal radiation after hysterectomy
This trial tests a short course of targeted vaginal radiation (brachytherapy) after surgery for certain early endometrial cancer. It may help prevent the cancer from coming back in the vaginal area after the uterus has been removed.
Palo Alto, CaliforniaAges Any age - NCT05548296RecruitingPhase 2
ACR-368 for high-grade endometrial cancer after prior treatments
This Phase 2 trial studies ACR-368 for people with high-grade endometrial cancer that has spread or grown despite at least one prior treatment. It may help by testing whether this drug can better control the cancer after other therapies have not worked.
Mobile, AlabamaAges 18 years+ - NCT05542407RecruitingPhase 1
ONC201 plus atezolizumab for endometrial cancer and obesity
This Phase 1 study tests ONC201 together with atezolizumab in people with metastatic or returning endometrial cancer, especially when obesity may be driving the cancer. It aims to find a safe dose and see whether the combination can slow the cancer’s growth.
Chapel Hill, North CarolinaAges 18 years+ - NCT05231122RecruitingPhase 2
Pembrolizumab and bevacizumab for recurrent ovarian cancer
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
Buffalo, New YorkAges 18 years+ - NCT05112601RecruitingPhase 2
Nivolumab plus or minus ipilimumab for dMMR endometrial cancer
This Phase 2 study tests the medicines nivolumab (with or without ipilimumab) in people with recurrent endometrial cancer that has “dMMR” (a specific tumor DNA repair defect). It aims to see whether this immune-based treatment can shrink tumors or help them stop growing.
Birmingham, AlabamaAges 18 years+ - NCT05059444Recruiting
Blood test to catch cancer early after treatment
This study looks for signs of cancer left in the body after treatment using a simple blood test (called a liquid biopsy). It aims to see if the test can catch cancer that might come back earlier than regular scans.
Birmingham, AlabamaAges 18 years+ - NCT05039801RecruitingPhase 1
Study drug IACS-6274 tested for advanced solid tumors
This Phase 1 study tests the experimental drug IACS-6274, sometimes with bevacizumab and paclitaxel, in people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and to learn whether the treatment can shrink or control cancer for certain tumor mutation types.
Houston, TexasAges 18 years+ - NCT05049538Recruiting
Liquid blood tests to predict endometrial cancer return
This trial studies whether blood “liquid biopsies” and tumor genetic testing can help predict whether endometrial cancer will come back after treatment. Results may help doctors plan follow-up and additional care based on a person’s recurrence risk.
Houston, TexasAges 18 years+ - NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
San Diego, CaliforniaAges 18 years+ - NCT07871838Recruiting
Shorter radiation course for endometrial cancer
This trial tests a shorter course of pelvic radiation for people with endometrial cancer after surgery. It aims to see if it is safe, works well, and improves quality of life.
Montreal, QuebecAges 18 years+ - NCT07436793RecruitingPhase 2
Progestin therapy before hysterectomy for endometrial cancer
This trial tests whether taking progestin (a hormone medication) before scheduled surgery can improve outcomes for women with a type of uterine cancer called endometrioid adenocarcinoma. You might be able to join if you are planning to have a hysterectomy and are open to hormone therapy before the procedure.
Iowa City, IowaAges 18 years+ - NCT04291612Recruiting
Observational study of standard surgery for uterine cancer in women
This is a research study that looks at outcomes in women with endometrial (uterine) cancer who receive the usual standard surgery. Researchers will group patients based on the final surgical and pathology results and what additional (if any) treatment is recommended afterward.
Hartford, ConnecticutAges 18 years+ - NCT06278857RecruitingPhase 2
Dostarlimab for early-stage MMR deficient endometrial cancer
This trial tests the drug dostarlimab for patients with early-stage endometrial cancer that is MMR deficient. It aims to see if the treatment is safe and effective for those who want to preserve their uterus or cannot have surgery.
Sydney, New South WalesAges 18 years+ - NCT07107334RecruitingPhase 2
GLP-1 drug plus hormone IUD for early endometrial cancer in obesity
This trial tests if adding a GLP-1 weight-loss drug to a hormone-releasing IUD can help treat very early endometrial cancer or a precancerous condition in women with obesity. The goal is to see if this combination is effective without surgery.
Gainesville, FloridaAges 18 years+ - NCT05579366RecruitingPhase 1/Phase 2
Study of rinatabart sesutecan for advanced solid tumors
This trial tests an investigational drug called rinatabart sesutecan (also known as Rina-S) for people with advanced solid tumors, including ovarian, endometrial, lung, breast, and other cancers. The drug is designed to target and kill cancer cells, and the study aims to see if it is safe and effective.
Phoenix, ArizonaAges 18 years+ - NCT03787056Recruiting
Blood test marker study in many cancer types
This study measures a blood marker called progastrin (at diagnosis and during treatment) to see how well it predicts response or outcomes. It may help doctors choose or monitor treatment more precisely for several cancer types.
BronAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial tests an experimental drug called NKT3964 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Little Rock, ArkansasAges 19 years+
Hear when a new Endometrial Clear Cell Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Endometrial Clear Cell Adenocarcinoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for endometrial clear cell adenocarcinoma?
- Yes. Clin2 currently lists 20 recruiting endometrial clear cell adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a endometrial clear cell adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a endometrial clear cell adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Clear Cell Renal Cell Carcinoma
- Metastatic Clear Cell Renal Cell Carcinoma
- Advanced Clear Cell Renal Cell Carcinoma
- Clear Cell Renal Cell Cancer (ccRCC)
- Fallopian Tube Clear Cell Adenocarcinoma
- Non-Clear Cell Renal Cell Carcinoma (nccRCC)
- Primary Peritoneal Clear Cell Adenocarcinoma
- Recurrent Ovarian Clear Cell Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.